GlassScriptPhysician profile
Izuchukwu E Nwakoby
NPI 1629076419
$5,533.74
in general payments reported to CMS, 2019-2025
34 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $306 · 2021: $120 · 2022: $813 · 2023: $907 · 2024: $744 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,707 · Travel and Lodging: $572 · Education: $90.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,707.20 |
| Travel and Lodging | $572.18 |
| Education | $90.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $960.85 | 2025 | Renal - Chronic, Renal - Pd |
| Astrazeneca Pharmaceuticals LP | $691.92 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $479.44 | 2019-2025 | Jynarque |
| Amgen INC. | $472.50 | 2019-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $348.26 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $299.86 | 2019-2023 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $222.63 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $201.46 | 2022-2024 | Ultomiris |
| Ardelyx, INC. | $195.00 | 2024-2025 | Ibsrela |
| Mallinckrodt Enterprises LLC | $179.95 | 2019 | |
| Horizon Therapeutics Plc | $178.61 | 2022-2023 | Krystexxa, Ravicti |
| Mallinckrodt Hospital Products INC. | $136.90 | 2025 | Terlivaz |
| Acelrx Pharmaceuticals, INC. | $120.02 | 2021 | |
| Calliditas Therapeutics US INC. | $119.71 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $112.79 | 2020-2025 | Velphoro, Korsuva, Velphoro |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $108.78 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.47 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $91.46 | 2019-2023 | Auryxia |
| Outset Medical INC | $80.23 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $74.67 | 2022 | |
| Boston Scientific Corporation | $58.34 | 2024 | Watchman Flx |
| Travere Therapeutics, INC. | $52.85 | 2022-2023 | |
| Lilly USA, LLC | $47.91 | 2024-2025 | Jardiance |
| Baxter Healthcare | $40.17 | 2020 | |
| Kyowa Kirin, INC. | $29.19 | 2023 | Crysvita |
| Aurinia Pharma U.S., INC. | $26.76 | 2022 | |
| Allergan, INC. | $26.07 | 2019 | |
| Glaxosmithkline, LLC. | $20.14 | 2024 | Benlysta |
| Novo Nordisk INC | $14.25 | 2023 | Ozempic |
| Cumberland Pharmaceuticals, INC. | $12.25 | 2020 | |
| Shire North American Group INC | $12.12 | 2019 | |
| Merck Sharp & Dohme LLC | $11.18 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Izuchukwu Nwakoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.